Breaking News
Home / Business / Biocon profit share on adalimumab biosimilar extended to global markets

Biocon profit share on adalimumab biosimilar extended to global markets


Biocon profit share on adalimumab biosimilar extended to global markets “Biocon, under the terms of its global partnership with Mylan for monoclonal antibodies, retains its economic interest in this expanded in-licensing arrangement and will gain a share of profits from Global Markets,” the statement added.

Check Also

Zomato hands pink slips to 10% workforce: Report

These were 10-15 percent of its overall workforce and the customer support team now has …

Leave a Reply

Your email address will not be published. Required fields are marked *